FDA, NIH look to streamline oversight of gene therapies
The FDA and NIH are proposing to further limit the role of the NIH and its Recombinant DNA Advisory Committee (RAC) in the review of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
